Share |
News

Verisante Technology, Inc. Partners with the BC Cancer Foundation to Showcase Aura™ for Skin Cancer Detection


June 10, 2014 at 1:30 pm

VANCOUVER, BRITISH COLUMBIA - Verisante Technology, Inc. (TSX-V: VRS, OTCQX: VRSEF) (the “Company” or “Verisante”), a leader in cancer detection technology, announced today that the Company is partnering with the BC Cancer Foundation to showcase Verisante Aura™, a device for the detection of skin cancer.

“We are very appreciative of the BC Cancer Foundation’s support for Verisante and for Aura™ and also for the Foundation’s dedication to raising funds that support innovative research directed at achieving the highest standard of care for every patient facing cancer in B.C.,” said Thomas Braun, President & CEO of Verisante Technology, Inc.

Verisante has placed an Aura™ at the Foundation’s Provincial Office in Vancouver for display and educational purposes.

“Our unique relationship with the BC Cancer Agency allows our donors to be part of research discoveries made right here in British Columbia,” said Douglas Nelson, President & CEO of the BC Cancer Foundation.  “Verisante Aura™ is one of those ‘made in BC’ inventions coming out of the leading edge technology and research efforts of the BC Cancer Agency. Our Foundation is pleased to have the opportunity to demonstrate and promote this exciting technology.”

The BC Cancer Foundation funds the areas of greatest priority and promise, as identified by the scientists and clinicians at the BC Cancer Agency, who look for priorities and needs that will have the most significant and timely impact on cancer care and treatment.  The Foundation then partners with donors to raise the necessary funds in support of this life-saving work.  Together with its partners, the Foundation is funding and finding solutions that are having a direct impact on improving care for cancer patients in British Columbia.

About the BC Cancer Foundation

The BC Cancer Foundation is the bridge that connects philanthropic support and research breakthroughs in cancer knowledge.  As the fundraising partner of the BC Cancer Agency and the largest charitable funder of cancer research in this province, we enable donors to make contributions to leading-edge research that has a direct impact on improvements to cancer care for patients in British Columbia.  We fund with the goal of finding solutions.

As an independent charitable organization, we raise funds exclusively for the BC Cancer Agency that support innovative cancer research and compassionate enhancements to patient care.  

Visit www.bccancerfoundation.com to make a donation or to learn how you can make a difference in the lives of those affected by cancer.

About Verisante Technology, Inc.

Verisante is a medical device company committed to commercializing innovative systems for the early detection of cancer. The Verisante Aura™ for skin cancer detection and the Verisante Core™ series for lung, colon and cervical cancer detection utilize a proprietary cancer detection platform, while the operating software and probe technology are unique to each device. The cancer detection platform was developed by the BC Cancer Agency and tested and refined at the Skin Care Centre at Vancouver General Hospital. This exclusive platform technology allows Verisante to develop and offer a range of compact, non-invasive cancer detection devices that offer physicians immediate results for many of the most common cancers. Aura™ has been approved for sale in Canada, Europe and Australia. Core™ has not yet been approved for sale. 

Verisante Aura™ was awarded the 2014 North American Technology Innovation of the Year Award for In Vivo Cancer Detection by Frost & Sullivan,  Popular Science Magazine’s “Best of What’s New Award” for 2011, awarded a 2013 Prism Award for Innovation in Photonics and an Edison Award for Excellence in Innovation in 2013. Verisante Core™ was named one of the top 10 cancer breakthroughs of 2011 by the Canadian Cancer Society. 

The TSX Venture Exchange has neither approved nor disapproved of the contents of this press release. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release. 

Company Contact:

Thomas Braun, President & CEO
Verisante Technology, Inc.
Telephone: (604) 605-0507
Email: info@verisante.com
Website:  www.verisante.com  
YouTube:  www.youtube.com/verisante  
Twitter: www.twitter.com/verisante
Facebook: www.facebook.com/verisante

Forward Looking Statements 

This release contains forward-looking statements, including, but not limited to, statements regarding the future commercialization of medical devices, the market demand for these products and the proprietary protections the Company will obtain with regard to the technology, all of which statements are subject to market risks, and the possibility that the Company will not be able to obtain patent protection or obtain sufficient customer demand. These statements are made based upon current expectations and actual results may differ from those projected due to a number of risks and uncertainties.

 

  Back to top